Covered recipient · General Payments record
SYED M MASE REHMAN
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$33,570.52
116 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,585.75 | 18 |
| Food and Beverage | $2,075.95 | 91 |
| Consulting Fee | $1,175.00 | 2 |
| Travel and Lodging | $720.39 | 2 |
| Education | $13.43 | 3 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $14,082.79 | 27 |
| GlaxoSmithKline, LLC. | $9,810.31 | 17 |
| Grifols USA, LLC | $3,544.43 | 5 |
| Acerta Pharma LLC | $3,169.70 | 11 |
| Amgen Inc. | $1,968.88 | 3 |
| CSL Behring | $187.13 | 10 |
| Octapharma USA, Inc. | $90.56 | 2 |
| GENZYME CORPORATION | $88.38 | 4 |
| Regeneron Healthcare Solutions, Inc. | $86.41 | 5 |
| PFIZER INC. | $82.86 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $78.85 | 5 |
| Optinose US, Inc. | $61.90 | 3 |
| AIMMUNE THERAPEUTICS, INC. | $56.77 | 3 |
| Teva Pharmaceuticals USA, Inc. | $55.78 | 3 |
| Merck Sharp & Dohme Corporation | $48.73 | 3 |
| Genentech USA, Inc. | $47.90 | 3 |
| BioCryst US Sales Co., LLC | $36.84 | 3 |
| Pharming Healthcare, Inc. | $28.98 | 2 |
| kaleo, Inc. | $27.99 | 2 |
| Horizon Therapeutics plc | $15.33 | 1 |
Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SYED M MASE REHMAN
NPI 1699775437 · CMS profile ID 31037
Allopathic & Osteopathic Physicians / Allergy & Immunology
TOLEDO, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1699775437?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SYED M MASE REHMAN, NPI 1699775437, CMS profile ID 31037. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699775437?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). SYED M MASE REHMAN, NPI 1699775437, CMS profile ID 31037. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699775437?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- SYED M MASE REHMAN, NPI 1699775437, CMS profile ID 31037, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1699775437?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
116 matching records · $33,570.52 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–116 of 116.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| CSL Behring | $29.01 | 03/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820165787 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.11 | 03/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820182101 | CMS |
| GENZYME CORPORATION | $18.88 | 03/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843451927 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $337.50 | 03/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820182093 | CMS |
| Grifols USA, LLC | $1,600.00 | 02/24/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846743897 | CMS |
| GlaxoSmithKline, LLC. | $15.41 | 02/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802090421 | CMS |
| GlaxoSmithKline, LLC. | $0.20 | 02/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802595707 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.98 | 02/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820182087 | CMS |
| Teva Pharmaceuticals USA, Inc. | $21.00 | 02/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839558533 | CMS |
| GlaxoSmithKline, LLC. | $8.49 | 01/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802886387 | CMS |
| Horizon Therapeutics plc | $15.33 | 01/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797190949 | CMS |
| AstraZeneca Pharmaceuticals LP | $73.81 | 01/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829719363 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $13.83 | 01/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820182081 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.35 | 01/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829353563 | CMS |
| BioCryst US Sales Co., LLC | $12.34 | 01/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849113599 | CMS |
| kaleo, Inc. | $16.66 | 01/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832126023 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $191.52 | 3 |
| PY2025 | Principal investigator | $576,557.09 | 76 |
| PY2024 | Principal investigator | $396,420.55 | 55 |
| PY2023 | Principal investigator | $488,717.96 | 58 |
| PY2022 | Principal investigator | $473,643.51 | 77 |
| PY2021 | Principal investigator | $412,725.11 | 120 |
| PY2020 | Recipient | $6,813.20 | 1 |
| PY2020 | Principal investigator | $315,684.69 | 45 |
| PY2019 | Recipient | $18,826.32 | 1 |
| PY2019 | Principal investigator | $594,885.76 | 69 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
79 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GENZYME CORPORATION | $700.00 | 12/15/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136513 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,339.79 | 12/11/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046958 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,000.00 | 12/03/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185552581 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $267.82 | 12/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208555053 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,614.00 | 11/24/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 | No dispute reported | 06/30/2026 | 1226136494 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,506.89 | 11/20/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046960 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,316.00 | 11/17/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136474 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22.58 | 11/15/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi | No dispute reported | 06/30/2026 | 1190304815 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $3,138.66 | 11/03/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208555023 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $265.77 | 11/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208555045 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,974.40 | 10/27/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL | a phase one,open label,single dose study to evaluate the pharmacokinetics of inhaled in adolescents with asthma | No dispute reported | 06/30/2026 | 1185552577 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,200.00 | 10/27/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype | No dispute reported | 06/30/2026 | 1226136442 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35.98 | 10/21/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244047010 |
| Principal investigator 1 | GENZYME CORPORATION | $4,110.00 | 10/20/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136439 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $551.31 | 10/14/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046962 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 10/06/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136417 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $8,080.82 | 10/02/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208555021 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $270.70 | 10/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208555037 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,799.07 | 09/25/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046964 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $173.78 | 09/15/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190305257 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,400.00 | 09/08/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136364 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,039.00 | 09/08/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 | No dispute reported | 06/30/2026 | 1226136406 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $270.20 | 09/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554941 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $34,607.54 | 08/27/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL | A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids | No dispute reported | 06/30/2026 | 1185552593 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $667.98 | 08/27/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046984 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $2,662.97 | 08/25/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554909 |
| Principal investigator 1 | PFIZER INC. | $1,339.39 | 08/23/2025 | Non-covered Recipient Entity ASTHMA ALLERGY CENTER | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228753293 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35.98 | 08/22/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244047008 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,093.77 | 08/19/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046966 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,293.49 | 08/13/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046982 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,038.60 | 08/11/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136337 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $68.20 | 08/05/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047000 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $267.47 | 08/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554939 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,325.30 | 08/01/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046980 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $3,220.63 | 07/28/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554911 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35.98 | 07/16/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244047006 |
| Principal investigator 1 | GENZYME CORPORATION | $1,050.00 | 07/14/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136593 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,400.00 | 07/14/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136572 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,836.75 | 07/14/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation | No dispute reported | 06/30/2026 | 1226136578 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 07/14/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136582 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35.98 | 07/03/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244047004 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $272.34 | 07/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554937 |
| Principal investigator 1 | PFIZER INC. | $14,042.00 | 06/26/2025 | Non-covered Recipient Entity Toledo Institute of Clinical Research Inc | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228790520 |
| Principal investigator 1 | GENZYME CORPORATION | $7,045.00 | 06/23/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136588 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $2,662.97 | 06/16/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554997 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $264.06 | 06/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208555009 |
| Recipient | Teva Pharmaceuticals USA, Inc. | $62.92 | 05/28/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244042993 |
| Recipient | Teva Pharmaceuticals USA, Inc. | $46.00 | 05/28/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244042995 |
| Recipient | Teva Pharmaceuticals USA, Inc. | $82.60 | 05/28/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244042997 |
| Principal investigator 1 | GENZYME CORPORATION | $1,050.00 | 05/27/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136569 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $5,325.94 | 05/19/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554999 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $12,000.00 | 05/16/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046978 |
| Principal investigator 1 | GENZYME CORPORATION | $2,450.00 | 05/12/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136565 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,900.00 | 05/12/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136561 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $260.58 | 05/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208555007 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $179.90 | 04/10/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244047002 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,650.00 | 04/07/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136548 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $5,223.48 | 04/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554995 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $249.32 | 04/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208555005 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $28,523.68 | 03/24/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL | The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod | No dispute reported | 06/30/2026 | 1185552595 |
| Principal investigator 1 | GENZYME CORPORATION | $2,100.00 | 03/17/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136534 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,877.70 | 03/17/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136544 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,236.29 | 03/06/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046954 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $242.07 | 03/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554979 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,551.42 | 02/24/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL | A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States | No dispute reported | 06/30/2026 | 1185552591 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $45,590.30 | 02/24/2025 | Non-covered Recipient Entity Toledo Institute Of Clinical Resear Inc | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226136541 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 02/23/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046998 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,209.07 | 02/19/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations | No dispute reported | 06/30/2026 | 1185552587 |
| Principal investigator 1 | AstraZeneca UK Limited | $54,095.68 | 02/13/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL | a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA | No dispute reported | 06/30/2026 | 1185552585 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $238.50 | 02/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554977 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $39,610.35 | 01/30/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL | A Multicentre,Randomised,Double Blind,Parallel Group,Placebo Controlled,52 week,Phase 3,Efficacy and Safety Study of Tezepelumab in 5 to 12 Year Old Children with Severe Uncontrolled Asthma HORIZON | No dispute reported | 06/30/2026 | 1185552589 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $551.31 | 01/30/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH INC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046956 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,052.90 | 01/17/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 | No dispute reported | 06/30/2026 | 1185552579 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $112.90 | 01/15/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi | No dispute reported | 06/30/2026 | 1190304817 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $59,393.11 | 01/03/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185552583 |
| Principal investigator 1 | Kedrion Biopharma, Inc. | $238.82 | 01/01/2025 | Non-covered Recipient Entity Asthma and Allergy Center - Toledo | KEDBEN60-0D1OMG | No dispute reported | 06/30/2026 | 1208554975 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $43,142.03 | 01/01/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190305255 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $965.56 | 01/01/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH | A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled | No dispute reported | 06/30/2026 | 1190305259 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $988.41 | 01/01/2025 | Non-covered Recipient Entity TOLEDO INSTITUTE OF CLINICAL RESEARCH | A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co | No dispute reported | 06/30/2026 | 1190305261 |